Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck already has a supply deal in place for molnupiravir with the US government, which has agreed a $1.2 billion order for 1.7 million doses at a price of $700 per course, as well as deals with ...

Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant ...

The US federal government has ordered another 1.4 million doses of Merck & Co and Ridgeback Biotherapeutics' oral antiviral molnupiravir for COVID-19, adding to an earlier agreement to supply 1.7 ...

Merck reported adjusted earnings of $1.72 per ... Supply constraints in China also hurt sales. Sales of Lagevrio (molnupiravir) declined 37% to $121 million in the quarter.

A panel of outside advisers to the U.S. health regulator will meet late next month to discuss whether to authorize Merck & Co's experimental ... of the drug, molnupiravir, for the treatment ...

60 Molnupiravir (Lagevrio; Merck), an oral antiviral prodrug of β-D-N4-hydroxycytidine that impairs SARS-CoV replication, received emergency use authorization (EUA) by the FDA in 2021; it is ...

Three antivirals are available in the US today: Pfizer’s Paxlovid, or nirmatrelvir with ritonavir; Gilead Sciences’ Veklury, or remdesivir; and Merck & Co.’s Lagevrio, or molnupiravir. All come with ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.